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Long-term cilostazol treatment 
reduces gliovascular damage 
and memory impairment in a 
mouse model of chronic cerebral 
hypoperfusion
Akihiro Kitamura1, Yasmina Manso1, Jessica Duncombe1, James Searcy1, Juraj Koudelka1, 
Margaret Binnie1, Scott Webster1, Ross Lennen1, Maurits Jansen1, Ian Marshall1, Masafumi 
Ihara  2, Raj N. Kalaria3 & Karen Horsburgh1
Chronic cerebral hypoperfusion is a major cause of age-related vascular cognitive impairment. A well-
characterised mouse model has shown that hypoperfusion results in gliovascular and white matter 
damage and impaired spatial working memory. In this study, we assessed whether cilostazol, a 
phosphodiesterase III inhibitor, could protect against these changes. Adult, male C57Bl/6J mice were 
subjected to bilateral common carotid artery stenosis or a sham operation and fed normal or cilostazol 
diet for three months. Cilostazol treatment reduced the impairment in working memory and white 
matter function after hypoperfusion. Endothelial adhesion molecules and gliosis, increased after 
hypoperfusion, were ameliorated with cilostazol treatment. Interestingly, the improvement in working 
memory was closely correlated with reduced microglia and endothelial adhesion molecules. Further, the 
number of stroke lesions after hypoperfusion was reduced in the cilostazol-treated group. Altogether 
cilostazol showed potential to ameliorate the gliovascular damage and working memory impairments 
after hypoperfusion possibly via endothelial protection supporting its potential use in the treatment of 
vascular cognitive impairment.
Vascular cognitive impairment (VCI) is a spectrum of age-related cognitive decline caused by vascular factors 
such as hypertension, atherosclerosis and diabetes1. One of the most common forms of VCI is small vessel disease 
which is associated with diffuse white matter injury, subcortical lacunar infarcts and microbleeds. The mecha-
nisms leading to VCI are ill-defined but disruption of the interplay between cells within the neuro-glio-vascular 
unit have been shown such as impaired vascular haemodynamics, endothelial dysfunction and compromise of the 
blood brain barrier (BBB). Another key and common mechanism linked to VCI is chronic cerebral hypoperfu-
sion which is induced by vessel narrowing and endothelial dysfunction. Cerebral hypoperfusion is now emerging 
as a major contributor to cognitive decline2.
Several animal models have been developed to investigate the mechanisms by which chronic hypoperfusion 
may lead to VCI. Of these, an experimental mouse model of chronic cerebral hypoperfusion, induced by bilateral 
carotid stenosis, is considered to be the most clinically relevant and has been widely used to probe mechanisms 
related to VCI. In this model, modest reductions in cerebral blood flow, akin to that observed in clinical VCI, can 
be reproduced using microcoils that when applied to both common carotid arteries restrict blood flow to the fore-
brain in mice. We have shown in this mouse model that cerebral hypoperfusion results in early (days to weeks) 
disruption of axon-glial integrity, myelin damage, microglial proliferation and spatial memory impairment3, 4 
with subsequent (3–6 months) gliovascular unit damage, BBB disruption and small vessel changes5. This tractable 
model provides a basis to test potential treatment strategies for VCI.
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To date there remains no effective treatments for VCI and instead current therapies are targeted to amelio-
rate the cognitive impairments via anti-cholinesterase approaches. Current drug developments are focussed on 
strategies to improve vascular health and the gliovascular unit6, 7. Since multiple mechanisms may be involved in 
VCI, drugs that have pleiotropic effects may be particularly useful. One such drug, cilostazol, a phosphodiesterase 
III inhibitor, is known to have neuro-glio-vascular protective effects through multiple mechanisms. Cilostazol is 
approved as an antiplatelet agent for the prevention and treatment of cerebral infarction and peripheral arterial 
disease. Cilostazol increases cAMP in vascular cells and can exert multiple beneficial effects on the vascula-
ture such as endothelial protection8, 9, maintenance of microvascular integrity10, vasodilation, anti-oxidation, 
anti-inflammation, regulation of smooth muscle cells11 and increase in cerebral haemodynamics12. There is 
now emerging evidence to suggest cilostazol may have beneficial effects in models of VCI and protect against 
white matter damage and cognitive impairment. However, to date the majority of these studies have focussed on 
the short-term effects of cilostazol over weeks13–16. The present study assessed whether cilostazol could protect 
long-term against the degenerative changes within the gliovascular unit and cognitive impairment induced by 
chronic cerebral hypoperfusion and whether it could exert beneficial effects on microvascular inflammation.
Results
Cilostazol had modest effects on spatial working memory after hypoperfusion. Spatial working 
memory has been shown to be selectively impaired in response to hypoperfusion3, 17. Similarly, the hypoper-
fused-control mice showed a clear impairment in this task and committed more revisiting errors (Fig. 1a) and 
performed less novel entries (Fig. 1a) than the sham mice throughout the test. Noteworthy, the hypoperfused-ci-
lostazol mice showed a learning process similar to shams up to block trial 4 (day 12 of test) before they plateaued 
(Fig. 1a) suggesting that the spatial memory impairment, whilst reduced, was not completely ameliorated with 
cilostazol treatment. Statistical analysis of the number of revisiting errors and novel entries indicated an overall 
Figure 1. Cilostazol improved spatial working memory and white matter function: (a) Spatial working memory 
was assessed using an 8-arm radial arm maze. Statistical analysis of the number of revisiting errors and novel 
entries indicated an overall significant difference between the 3 groups (F(2, 34) = 5.169; p = 0.029 and F(2, 
34) = 5.718; p = 0.022, respectively). Hypoperfused-control mice exhibited significantly more revisiting errors 
and less novel entries than the sham operated mice (p < 0.05 and p < 0.05), while hypoperfused-cilostazol mice 
showed a learning process similar to that of sham mice before they plateaued. Data represents the average of 4 
trials for block 1 and 2 and the average of 2 trials for blocks 3–6. (b) In the corpus callosum, evoked compound 
actions potentials (CAPs) were recorded at various distances from the stimulating electrode. Peak latencies 
of CAPs were significantly different between the three groups (F(2,12) = 14.78; p = 0.0048). The peak latency of 
CAPs in hypoperfused-control mice was overall significantly increased compared to sham mice (p < 0.01) but 
this was ameliorated with cilostazol treatment. Data represents mean ± SEM. **p < 0.01, Hypoperfused-control 
vs Sham.
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significant difference between the 3 groups (F(2,34) = 5.169; p = 0.029 and F(2,34) = 5.718; p = 0.022, respectively). 
Post-hoc analysis indicated that there was a significant difference in the number of revisiting errors and novel 
entries between the hypoperfused-control and the sham group (p < 0.05), but there was no difference between the 
hypoperfused-cilostazol and sham group (p > 0.05). This data suggests that the chronic treatment with cilostazol 
has modest beneficial effects on spatial working memory after long term hypoperfusion.
Cilostazol improved white matter function. We have previously demonstrated that chronic cerebral 
hypoperfusion causes diffuse white matter changes3. To build on this work, we determined whether the func-
tional integrity of white matter was altered in response to hypoperfusion and if this was ameliorated by cilosta-
zol. Peak latencies of compound action potentials (CAPs) were significantly different between the three groups 
(F(2, 12) = 14.78; p = 0.0048) Post-hoc analysis indicated that the peak latency of CAPs in hypoperfused-control 
mice were significantly increased compared to shams (p < 0.01). However, the peak latencies of CAPs in the 
hypoperfused-cilostazol group were not significantly different to those of sham mice (p > 0.05) (Fig. 1b). These 
results suggest that hypoperfusion significantly impedes the conduction velocity of myelinated fibers and that 
cilostazol treatment is able to reduce this deficit.
Cilostazol did not significantly restore white matter integrity. Since white matter function was 
found to be compromised with hypoperfusion and restored with cilostazol treatment, we next evaluated white 
matter integrity using diffusion tensor imagingimaging (DTI) and pathological analysis (myelin associated glyco-
protein, MAG, immunostaining). There was no significant difference in fractional anisotropy (FA) in the corpus 
callosum between the groups (F(2,33) = 2.513; p = 0.097) (Fig. 2a). However it was noted that there was a modest 
reduction in FA between the sham and hypoperfused-control groups (0.47 ± 0.01 vs. 0.40 ± 0.03), consistent with 
a previous report18. Cilostazol treatment did not have any effect on FA (0.40 ± 0.02). Interestingly, there was a 
significant negative correlation between FA and the number revisiting errors made on the radial arm maze test 
with mice committing more errors having lower FA values which are indicative of a more disrupted white matter 
architecture (Fig. 2b) (Spearman r = −0.583, p = 0.0003).
There was a significant difference in MAG staining between the three groups (p = 0.0003). Post-hoc anal-
ysis indicated that there was a significant loss of axon-glial integrity (identified by MAG immunostaining) in 
the hypoperfused-control compared to the sham mice in the corpus callosum (p < 0.001). However, the loss of 
axon-glial integrity was also found to be significantly different in the hypoperfused-cilostazol mice as compared 
to sham mice (p < 0.05) (Fig. 2c) indicating that cilostazol was unable to improve axon-glial disruption after 
hypoperfusion.
Figure 2. Cilostazol did not significantly restore white matter integrity. (a) There was no significant difference 
in Fractional Anisotropy (FA) in the corpus callosum between the three groups. (b) A significant relation 
between FA and revisiting errors was determined (Spearman r = −0.583, p = 0.0003). (c) MAG grading, as an 
index of breakdown in axon-glial integrity, was significantly increased after hypoperfusion, but no protective 
effect of cilostazol could be observed. Data represents mean ± SEM. **p < 0.001, Hypoperfused-control vs 
Sham; **p < 0.05, Hypoperfused-Cilostazol vs Sham.
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Cilostazol improved cellular neuroinflammation. A prominent feature of hypoperfusion is a robust 
cellular neuroinflammatory response. Consistent with this, microglial activation (identified by the extent of Iba1 
immunostaining) was increased in the corpus callosum after hypoperfusion (Fig. 3a) but in this study we found 
no significant overall effect between the 3 groups (F(2, 33) = 2.866; p = 0.072). However the results did indicate 
that there was an increase in the density of Iba1 positive staining following hypoperfusion which was lower with 
cilostazol treatment (8.26 ± 1.47 vs 6.61 ± 1.05) (Fig. 3b). Notably, there was a robust association between the 
extent of Iba1 staining in the corpus callosum and revisiting errors (Fig. 3b, Pearson r = 0.712, p < 0.0001), indi-
cating that higher levels of cellular neuroinflammation correlate with poorer spatial working memory. Similarly, 
in the corpus callosum there was an overall difference in the extent of reactive astrogliosis (glial fibrillary acidic 
protein, GFAP, immunostaining) (p = 0.04). It was found that GFAP immunostaining was significantly reduced 
after hypoperfusion with cilostazol treatment (p < 0.05) (Fig. 3c and d).
To explore potential dynamic changes in gliovascular unit, alterations in the protein aquaporin 4 (AQP4) 
were investigated. AQP4 is a water channel typically confined to the endfeet of vascular associated astrocytes 
and is reported to maintain osmotic balance and to lose the polarization to the perivascular endfeet related 
to the development of microinfarcts19, 20. Mislocalisation of the water channel AQP4 (as measured by % area 
AQP4) was observed in the hypoperfused-control mice compared to sham mice consistent with our previous 
study5 and cilostazol tended to revert this redistribution (Sham; 0.67 ± 0.25, Hypoperfused-control; 4.31 ± 3.21, 
Hypoperfused-cilostazol; 2.20 ± 0.56, p = 0.12) (Fig. 3d).
Cilostazol significantly suppressed endothelial adhesion molecule expression. In order to eluci-
date the mechanism by which cilostazol reduces glial activation, we measured endothelial activation, previously 
shown to be linked to beneficial effects of cilostazol8–10. Intercellular adhesion molecule-1 (ICAM1), a marker 
of endothelial cell activation21, was investigated. There was a significant difference in ICAM between the three 
groups (F(2, 33) = 13.19; p < 0.0001). A significant increase in ICAM1 immunostaining was determined in the 
corpus callosum in the hypoperfused-control group compared to both the sham and hypoperfused-cilostazol 
groups (p < 0.001 and p < 0.01) (Fig. 4a and b). Supportive of a close relation between endothelial cell activation, 
microgliosis and memory, a significant association between ICAM1 and Iba1 immunostaining was determined 
(Pearson r = 0.375, p = 0.029), and a significant association between ICAM1 and the number of revisiting errors 
(Pearson r = 0.412, p = 0.016) (Fig. 4c) was determined in the corpus callosum.
Cilostazol reduced stroke lesions but did not affect baseline CBF. Following on from the finding 
that cilostazol had a beneficial effect on endothelial cell activation, we determined whether this may also impact 
on baseline cerebral blood flow (CBF) using arterial spin labelling (ASL). There was an overall difference in 
CBF between the three groups in the corpus callosum (F(2, 25) = 11.0; p = 0.0004) and thalamus (F(2, 25) = 33.05; 
p < 0.0001). CBF was significantly reduced in hypoperfused-control and hypoperfused-cilostazol mice com-
pared to sham mice in the corpus callosum (p < 0.001 and p < 0.001) and the thalamus (p < 0.001 and p < 0.001) 
(Fig. 5a and b). Stroke lesions (ischemic and hemorrhagic), detected on T2-MRI (Fig. 6a), were present after 
hypoperfusion but absent from all sham mice. Interestingly, cilostazol was found to decrease the number of 
the ischemic stroke lesions (present in only 2 of 13 (15%) hypoperfused-cilostazol mice versus 6 of 11 (55%) 
hypoperfused-control mice) (Fig. 6b).
Discussion
The current study is of the first to report the beneficial long-term effects of cilostazol in a model of chronic cer-
ebral hypoperfusion relevant to the pathophysiology of VCI. Cilostazol exerted a protective effect against white 
matter dysfunction and modestly improved spatial working memory at 3 months after cerebral hypoperfusion. 
These improved functional outcomes were closely related to reduced gliovascular damage, cellular inflammation 
and endothelial activation.
Previous studies have indicated that cilostazol protects against hypoperfusion-induced white matter damage13–16  
contrary to the present study in which cilostazol was found to have minimal impact on white matter integrity. The 
effects of cilostazol have been predominantly studied in more severe models of cerebral hypoperfusion such as a 
rat 2-vessel occlusion (2VO) model and within 1 to 5 weeks hypoperfusion13–15. The rat 2VO model shows marked 
BBB disruption, as early as 3 days post-operation22, leading to prominent white matter lesions, glial activation and 
profound impairment of various aspects of cognition15, 23, 24. In contrast, our mouse model of cerebral hypoperfu-
sion shows gradual and progressive temporal changes of white matter dysfunction, gliovascular unit disruption 
and glial activation leading to working memory impairment3, 5. In our model, there is minimal disruption of the 
BBB until 6 months post-hypoperfusion5 whereas there is marked BBB damage in the rat 2VO models which may 
enhance movement of cilostazol directly to the brain25. There are also differences in the severity of hypoperfu-
sion, BBB and white matter damage between the different laboratories that study the mouse model of cerebral 
hypoperfusion16. We have previously shown that there are subtle changes in the distribution of paranodal-nodal 
proteins with hypoperfusion4 that were not measured in the present study. This redistribution of the molecular 
architecture of myelinated axons can impact on white matter function. In support of this, despite the lack of 
protection against white matter changes, cilostazol was able to improve white matter function as assessed using 
electrophysiological approaches and improve spatial working memory which is dependent on frontal cortical 
circuitry. Increased microglial density accompany hypoperfusion-induced damage to white matter3–5, 15, 16 and 
may contribute to the damage via pro-inflammatory mechanisms. Notably increased microglia were determined 
in the corpus callosum of hypoperfused mice and reduced by cilostazol-treatment. Furthermore, it was found that 
the extent of microgliosis in white matter relates to the impairment in working memory. A previous study has also 
www.nature.com/scientificreports/
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Figure 3. Cilostazol reduced the extent of gliosis. (a) Representative images of Iba1 staining in the corpus 
callosum. (b) There was a trend towards an increase in Iba1 stained micoglia that was reduced with cilostazol 
after hypoperfusion. There was a robust association between microgliosis and the number of revisiting 
errors (Pearson r = 0.712, p < 0.0001). (c) Representative images of immunofluorescence for Collagen IV, 
AQP4 and GFAP in the corpus callosum. (d) There was an increase in the area of GFAP positive astroglia in 
the hypoperfused-control mice. There was a significant reduction with cilostazol treatment as compared to 
control hypoperfused. Astrocyte-endfoot displacement tended to be observed in the hypoperfused-control 
mice and less in the cilostazol treated mice. Data represents mean ± SEM. *p < 0.05, Hypoperfused-control vs 
Hypoperfused-cilostazol.
www.nature.com/scientificreports/
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shown beneficial effects of cilostazol on microglia and anti-inflammatory pathways26. Thus neuroinflammation 
is proposed to be strongly associated with white matter dysfunction and working memory impairment (Fig. 7).
Endothelial dysfunction is widely considered to be one of the pivotal mechanisms of the structural and func-
tional brain-vessel alterations in small vessel disease (SVD) and evidence has accumulated to support the hypoth-
esis that early endothelial failure is a major precipitant of sporadic SVD27, 28. Endothelial damage can lead to 
increased permeability, damage to vessel wall, dysregulation of vascular tone, inflammation, demyelination, gliosis 
and at a late stage, luminal narrowing and thrombosis21, 27. White matter lesions are characterized by the expres-
sion of adhesion molecules such as ICAM128, which are induced by proinflammatory cytokines that promote 
the adherence of monocytes. The increased expression of ICAM1 may reflect endothelial dysfunction or micro-
vascular inflammation; ICAM1 expression is recognized mainly in the endothelial cells but can also be found 
in microglia and leukocytes. In the current study, ICAM1 staining, as an index of endothelial dysfunction, was 
markedly increased with hypoperfusion and restored with cilostazol treatment. Additionally endothelial dysfunc-
tion was significantly correlated with neuroinflammation and spatial working memory impairment. Thus the data 
suggest that cilostazol might restore endothelial dysfunction without apparent BBB disruption leading to damp-
ening of glial activation, improved white matter function and cognition (Fig. 7, large arrows). However whether 
this is a direct effect of cilostazol on endothelial cells or secondary to other effects, for example on microglia26, 
remains to be determined. Interestingly cilostazol has been shown to have effects on spatial learning in control 
mice via effects on growth factors29. Thus cilostazol appears to have multiple beneficial effects. Future studies 
could define whether endothelium dependent vasodilator agents afford similar protection in the hypoperfusion 
model in vivo in comparison to cilostazol treatment. Similarly, in animal models relevant to Alzheimer’s disease 
Figure 4. Cilostazol significantly suppressed endothelial adhesion molecule expression in the corpus callosum. 
(a) Representative images of intercellular adhesion molecule-1 (ICAM1) staining in the corpus callosum. (b) 
There was a significant difference in ICAM staining between the three groups (F(2, 33) = 13.19; p < 0.0001). 
ICAM1 immunostaining was significantly greater in the hypoperfused-control group compared to the sham 
(p < 0.001) and this was reduced with cilostazol treatment (p < 0.01). (c) There was a significant association 
between ICAM1 positive areas and microgliosis (Pearson r = 0.375, p < 0.05), and the number of revisiting 
errors (Pearson r = 0.412, p < 0.05). Data represents mean ± SEM.
www.nature.com/scientificreports/
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(AD), increased endothelial adhesion molecules have been highlighted as markers of endothelial dysfunction 
and vascular inflammation30. Endothelial dysfunction may be a common target in the treatment of AD, VCI and 
vascular dementia. Our present study supports the utility of cilostazol in the treatment of VCI. A previous study 
has also indicated beneficial effects of cilostazol in a mouse model relevant to AD through increased amyloid β 
clearance due to improved cerebrovascular function31. Retrospective clinical studies indicated the potential for 
cilostazol treatment to suppress cognitive decline in elderly patients with mild dementia or cognitive impair-
ment32, 33. However the current study suggests that whilst cilostazol improves hypoperfusion- induced memory 
deficits these are not completely restored, the improvement in memory plateaued after 12 days of testing. The 
current studies were also conducted in mid-age rodents and further studies should include aged cohorts where 
the pathological and functional impairments to hypoperfusion may be exacerbated and be affected differently by 
cilostazol.
Although cilostazol is well known for its vasodilatory effect via up-regulation of cAMP, there was no effect of 
cilostazol determined on CBF measures in the corpus callosum and the thalamus at 3 months post-operation. 
These results are consistent with other studies13, 14, which indicated that CBF was not significantly influenced by 
cilostazol despite demonstrations that white matter damage is restored in the cilostazol treated mice14. Similarly, 
although there was a reduction in the number of stroke lesions with cilostazol this was not paralleled by an 
increase in CBF. In this study it is difficult to precisely relate the CBF measures with stroke lesions since the CBF 
measures using ASL were conducted at one brain level whereas the stroke lesions were found throughout different 
levels of the brain and in different brain regions. There may be other effects of cilostazol that are independent of 
perfusion. For example, restoration of endothelial dysfunction by cilostazol directly or indirectly via microglia33 
might reduce the number of stroke lesions without an effect on perfusion (Fig. 7). Vasomotor reactivity or neuro-
vascular coupling, which are recognized to be associated with cognitive impairment34, 35 might also be impaired 
by hypoperfusion and remain to be elucidated.
Our study showed that cilostazol ameliorated gliovascular damage and working memory impairment possi-
bly via endothelial protection in a mouse model of chronic cerebral hypoperfusion. This evidence indicates that 
cilostazol, originally a drug for stroke and peripheral arterial disease, might be a useful candidate for the treat-
ment of VCI. However, these beneficial effects of cilostazol are modest in this model of VCI and thus other more 
potent drugs need to be considered.
Methods
Animals and surgical procedure. All experiments were conducted under the UK Home Office Animals 
(Scientific Procedures).
Act 1986, in agreement with local ethical and veterinary approval (Biomedical Research Resources, University 
of Edinburgh) and the ARRIVE guidelines. Adult (25–30 g, approx. 4–5 months old) male C57Bl/6J mice (Charles 
River Laboratories Inc., UK) were used for all experiments. Mice underwent chronic cerebral hypoperfusion 
Figure 5. Cilostazol did not affect cerebral blood flow. (a) Representative images of ASL at the level of 
hippocampus. (b) There was an overall difference in CBF between the three groups in the corpus callosum (F(2, 
25) = 11.0; p = 0.0004) and thalamus (F(2, 25) = 33.05; p < 0.0001). CBF was significantly reduced in hypoperfused-
control and hypoperfused-cilostazol mice compared to sham mice in the corpus callosum (p < 0.001 and 
p < 0.001) and the thalamus (p < 0.001 and p < 0.001). Data represents mean ± SEM.
www.nature.com/scientificreports/
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Figure 6. Cilostazol reduced stroke injury. (a) Representative images of T2-MRI detecting the ischemic (arrow 
head) and hemorrhagic (arrow) lesions. (b) MRI analysis showed that cilostazol remarkably decreased the 
number of the ischemic stroke lesions after chronic hypoperfuson.
Figure 7. A proposed mechanism by which cilostazol may improve cognitive impairment induced by 
chronic cerebral hypoperfusion. Cilostazol reduced the number of stroke lesions and significantly ameliorated 
the spatial working memory impairment and white matter dysfunction induced by chronic cerebral 
hypoperfusion. Remarkably, cognitive deficits seem to be closely associated with the hypoperfusion-induced 
neuroinflammatory processes which are significantly decreased with cilostazol treatment. Cilostazol might 
restore endothelial dysfunction without apparent BBB disruption leading to recovery of neuroinflammation and 
white matter dysfunction (large arrow).
www.nature.com/scientificreports/
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via bilateral common carotid artery stenosis3–5 using microcoils fitted on both common carotid arteries under 
isoflurane anaesthesia (induced at 5% and maintained at 1.5%). Sham mice underwent the exact same surgical 
procedure with the exception that coils were not applied to the arteries. Mice were fed with either pelleted chow 
containing 0.3% cilostazol (cilostazol-treated mice) or standard pelleted chow only (control-treated mice) from 
one week before the surgery.
Animal cohorts and exclusions. Mice were coded and randomly divided into different groups (1) 
sham-control, (2) hypoperfused-control, and (3) hypoperfused-cilostazol. Two different cohorts were stud-
ied: Cohort 1 in which the mice were assessed using Radial Arm Maze, Magnetic Resonance Imaging (MRI) 
with endpoints of pathology; Cohort 2; mice were studied using electrophysiology. Investigators were blinded 
to the surgical or drug intervention until the final analysis. Cohort 1 Initial numbers at the outset of study 
were: sham-control n = 10, hypoperfused-control n = 12, hypoperfused-cilostazol n = 13. One mouse in the 
hypoperfused-control group was culled due to poor recovery before the MRI scan. The final numbers for behav-
iour, were sham-control n = 10, hypoperfused-control n = 12, hypoperfused-cilostazol n = 13. The final numbers 
for MRI (T2/DTI) were sham-control n = 10, hypoperfused-control n = 11, hypoperfused-cilostazol n = 13. ASL 
was assessed in a subset of these since one mouse in sham-control, four mice in hypoperfused-control and three 
mice in hypoperfused-cilostazol group were excluded due to poor quality of ASL. Thus the final group sizes for 
ASL were: sham-control n = 9, hypoperfused-control n = 7, hypoperfused-cilostazol n = 10. Cohort 2: Initial 
numbers at the outset were sham-control n = 4, hypoperfused-control n = 6, hypoperfused-cilostazol n = 5. 
Electrophysiology recordings could not be made in two mice: one hypoperfused control and one hypoperfused 
cilostazol. Thus the final numbers for electrophysiology were sham-control n = 4, hypoperfused-control n = 5, 
hypoperfused-cilostazol n = 4.
Radial Arm maze. Spatial working memory was assessed using an 8-arm radial maze. Mice were food 
deprived to reduce their initial body weight by 10–15% and the restricted feeding was maintained until the end 
of behavioural testing. Two pretraining days were undertaken in order to familiarize the animals with the exper-
imental environment, the apparatus and the task itself (see supplementary methods). For the training procedure 
one food pellet was placed at the end of each of the 8 arms of the maze. At the beginning of every trial (one trial/
day) the animal was placed on the central platform with all arm doors open and allowed to make an arm choice. 
An arm choice was recorded when the centre of the mouse (as tracked by the AnyMaze software) was 5 cm into 
the arm. Once the mouse had entered one of the arms, the doors to the other 7 arms were closed automatically. 
When the animal exited the visited arm it was confined on the central platform for 5 sec by closing the remaining 
door. After the 5 sec delay it was allowed to make a new choice. A trial ended when the mouse had retrieved all 
8 pellets or 25 min had elapsed. The behavioural testing lasted 16 days. For each trial, the number of correct arm 
entries within the first eight visits, the number of revisited arms (working memory errors) and the time taken to 
complete the task were recorded. Data were expressed as the mean of 4 trial blocks for the first 8 days and 2 trial 
blocks for the rest of 8 days.
Magnetic Resonance Imaging. Neuroimaging was conducted on completion of the behavioural 
assessment. Mice were anaesthetised and placed in an MRI compatible holder (Rapid Biomedical, Wurzburg, 
Germany). Rectal temperature and respiration were monitored and controlled throughout to ensure normal 
physiological parameters. Structural T2-weighted and DT- MRI data were collected using an Agilent 7 T preclin-
ical MRI scanner (Agilent Technologies, Yarnton, UK); with a 72 mm volume coil and a 2 channel phased array 
mouse brain coil (Rapid Biomedical). Arterial Spin Labelling (ASL) was performed using a Look-Locker FAIR 
single gradient echo (LLFAIRGE) sequence (see supplementary methods for details).
T2-weighted MRI slices of the mouse brain (1.0 to − 4.6 mm Bregma) were examined for (i) the presence 
and type of cortical and/or subcortical primary ischaemic lesions and (ii) primary haemorrhages and anatomical 
location3 (supplementary methods). The number of ischaemic and hemorrhagic lesions were determined and 
the percentage of mice with lesions in each cohort calculated. Fractional Anisotropy (FA) was generated using 
‘in-house’ custom software. FA and ASL techniques were processed by regions of interest (ROIs) analysis. ROIs 
were set in the thalamus and the corpus callosum at the levels of the striatum and the hippocampus for FA and at 
the level of hippocampus for ASL.
Immunohistochemistry. Mice were transcardially perfused with 4% paraformaldehyde (PFA) under 
deep anaesthesia (5% isoflurane in oxygen enriched air) and brains were carefully removed, postfixed in 4% 
PFA for 24 hours and processed for cryostat sectioning. Coronal brain sections were cut using a cryostat and 
mounted onto superfrost slides (10 µm) or preserved in cryoprotective medium at −20 °C (30 µm). All sections 
except for ICAM1 staining were heat-retrieved with either EDTA pH 8 or citrate pH 6 and primary antibodies 
were incubated overnight at 4 °C in blocking buffer (see supplementary data for further details). Subsequently, 
the sections were incubated with biotinylated secondary antibodies (1:100; Vector Labs) and a solution of 
streptavidinbiotin-peroxidase complex or alternatively with fluorescent secondary antibodies (Alexa Fluor, 
Thermofisher; 1:500). Peroxidase activity was localised using 3,3′ diaminobenzadine tetrahydrochloride (DAB) 
as a chromagenic substrate (Vector Labs). DAB immunolabeled sections were analyzed using an optical micro-
scope Olympus BX51 and fluorescent immunolabeled sections were analyzed using a laser scanning confocal 
microscope Leica SP5 C. All measurements were done in the corpus callosum using imageJ. To assess micro-
glial activation, expression of endothelial adhesion molecule and activation of astrocytes, positively stained area 
of Iba1, ICAM1 and GFAP were measured respectively. The loss of axon-glial integrity of the corpus callosum 
(disorganised white matter fibres, presence of myelin debris and vacuolation) was assessed using MAG antibody 
and graded from 0 (none) to 3 (extensive) as previously described3. Percentage area stained by AQP4 and COL4 
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as well as their respective colocalization (Manders coefficient) was determined after being equally thresholded 
across all sections for the respective antibody. The measure of AQP4 out with vessels was defined as the difference 
between percentage area stained by AQP4 and COL4, respectively.
Electrophysiology. Three months after surgery, mice were sacrificed and their brains were quickly removed 
on top of a frozen petri-dish with a few drops of sucrose artificial cerebrospinal fluid (aCSF) (189 mM Sucrose, 
10 mM D-glucose, 26 mM NaHCO3, 3 mM KCl, 5 mM MgCl2, 0.1 mM CaCl2, 1.25 mM NaH2PO4). The brain 
was then rapidly dissected, placed in a cell strainer and submerged in ice-cold oxygenated sucrose aCSF for 
2–3 minutes. Sections were then cut at 400 μm using a vibrating blade microtome (Hydrax V50, Zeiss, Cambridge, 
UK). A single coronal slice (−1.2–1.7 mm Bregma) was then transferred to a warmed (34 °C) incubation cham-
ber (BSK1, Digitimer, Welwyn Garden City, UK) with oxygenated aCSF (124 mM NaCl, 5 mM KCL, 1.25 mM 
NaH2PO4, 26 mM NaHCO3, 1.3 mM MgSO4, 2 mM CaCl2, 10 mM D-Glucose). Following at least a 1 hour period 
of post-slicing recovery slices were carefully transferred to a recording chamber (RC27L, Harvard Apparatus, 
Cambridge, UK) and mounted on an Olympus BX51 microscope where they were superfused with oxygenated 
aCSF (2–3 ml/min) at 24 °C. This temperature was employed to enable discrimination of compound actions 
potentials (CAP) arising from myelinated and unmyelinated fibres. Slices were supported by a slice anchor and 
then allowed to rest for 30 minutes prior to recording. A bipolar stimulating electrode (WPI Inc, Hertfordshire, 
UK) with manually blunted tips was lowered into the corpus callosum ~1 mm lateral to the midline using a man-
ual manipulator and constant current stimulus-isolated square wave pulses (NL800, Digitimer, Welwyn Garden 
City, UK) were applied to evoke CAPs. Recording electrodes were pulled from borosilicate glass capillaries 
(1.5/0.84 mm OD/ID, 100 mm long, WPI Inc., Hertfordshire, UK) and back filled with aCSF to give a final resist-
ance of 1–3 MΩ. These were connected to the amplifier’s headstage via an Ag/AgCl wire and then lowered into the 
corpus callosum (Patchstar micromanipulator, Scientifica, East Sussex, UK) adjacent to the midline 2.5 mm con-
tralateral to the stimulating electrode. For analysis of the CAP peak amplitude standardised input-output func-
tions were generated by varying the intensity of stimulus pulse (200 μs duration, 0.2 Hz) in 0.25 mA increments 
from 0.25–4 mA. To enhance the signal to noise ratio, all electrophysiology analysis was conducted on averaged 
waveforms of four successive sweeps. Evoked CAPs were amplified (x500) and filtered (bandpass = DC to 10 kHz) 
using an Axopatch 200 A amplifier in voltage following mode (Molecular Devices, Berkshire, UK). Responses 
were digitized at 200 kHz, and recorded for offline analysis using pClamp software (v10, Molecular Devices, 
Berkshire, UK). CAPs were evoked at the maximal stimulation of 4 mA and the distance between the stimulating 
and recording electrode altered in 0.5 mm increments from 1–2.5 mm by moving the recording electrode. The 
post-stimulus latency of the CAP peak was then measured.
Statistical analysis. All values are expressed as mean ± standard error of the mean (SEM). One-way analysis 
of variance (ANOVA) was used to evaluate significant differences among groups followed by a post hoc Tukey test. 
When data was not normally distributed, non-parametric tests were applied (Kruskal-Wallis). Semi-qualitative 
MAG grading was analysed with Kruskal-Wallis test for trend. Spearman’s or Pearson’s rho was used to evaluate 
the correlation betweeen data sets. Differences with p < 0.05 were considered significant in all statistical analyses.
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